The opportunity exists to express interest in an investment into Mastaplex Limited.
Mastaplex is poised to become a leading provider of point-of-care diagnostic tests for mastitis in dairy cows, supporting veterinarians and farmers around the globe with antibiotic treatment decisions. Mastitis is one of the most prevalent and costly diseases of dairy cows worldwide. The economic losses associated with mastitis stem from mainly discarded milk but also from decreased milk production and quality and increased labour and treatment costs. The company’s products and services support disease management, improved food quality, and combat against antimicrobial resistance. It has developed a proprietary mastitis testing device Mastatest which provided faster and more precise mastitis diagnosis on farm. Mastatest, is a world-leading and patent-protected solution that provides dairy farmers and vets with easy, accurate, and rapid bovine mastitis diagnoses. A cloud-based IT solution, Mastaplex is able to advise a farmer which cow has which bug within 24 hours, helping decrease antibiotic use.
Mastatest is now available in the European Union, North America, New Zealand, Australia and Africa, with more than 1,000 farmers using the solution to date.
Mastaplex was founded by Dr Olaf Bork and is based in Dunedin within the Centre for Innovation (University of Otago campus). This position provides access to world class research infrastructure and embeds Mastaplex Ltd in a vibrant, well-supported entrepreneurial space. Mastaplex Ltd was incubated in 2015 through WNT Ventures with the support of Callaghan Innovation and is supported by K1W1, NZGCP, LIC, Enterprise Angels among other investors with the goal to accelerate innovation and to build a global company.
For more information, Register Interest and the company will be in touch.